In the latest trading session, Pfizer (PFE) closed at $29.40, marking a -0.61% move from the previous day. The stock's performance was behind the S&P 500's daily loss of 0.15%. Elsewhere, the Dow lost 0.42%, while the tech-heavy Nasdaq added 0.09%.Heading into today, shares of the drugmaker had gained 3.28% over the past month, lagging the Medical sector's gain of 6.58% and the S&P 500's gain of 3.5% in that time.The investment community will be closely monitoring the performance of Pfizer in its forthcomin ...

Pharmaceutical giant Pfizer (PFE 0.37%) went through a growth spurt during the COVID-19 pandemic as one of the leading vaccine companies. But the windfall of billions of extra dollars in revenue and profits has gone as quickly as it came.Today, Pfizer stands roughly where it did before COVID-19 and shares trade at their lowest levels since the initial pandemic market crash in 2020. Is the stock a long-term buy after recently completing a blockbuster $43 billion acquisition?Here is what investors need to kno ...

Pfizer (PFE 0.37%) had a disastrous 2023, with its share price collapsing by 44%. It was one of the S&P 500's worst-performing stocks last year. The company's COVID-19 revenue nosedived as the demand for vaccinations waned, and the drugmaker can no longer count on that being a strong growth driver for the business.But with such a beaten-down valuation and Pfizer back to trading at 2020 levels, has the stock become too cheap of an investment to pass up? Is it only a matter of time before its shares rally aga ...

Pfizer Inc. (NYSE:PFE) J.P. Morgan 42nd Annual Healthcare Conference January 9, 2024 6:00 PM ET Company Participants Albert Bourla - Chairman and Chief Executive Officer Conference Call Participants Chris Schott - J.P. Morgan Chris Schott Good afternoon, everybody. I'm Chris Schott at J.P. Morgan, and it's my pleasure to be hosting a fireside chat today with Albert Bourla, Chairman and CEO of Pfizer. So, Albert, happy New Year. Thanks for joining us. I know you want to make some quick opening remarks and th ...

Pfizer Inc. (NYSE:PFE) J.P. Morgan 42nd Annual Healthcare Conference January 9, 2024 6:00 PM ET Company Participants Albert Bourla - Chairman and Chief Executive Officer Conference Call Participants Chris Schott - J.P. Morgan Chris Schott Good afternoon, everybody. I'm Chris Schott at J.P. Morgan, and it's my pleasure to be hosting a fireside chat today with Albert Bourla, Chairman and CEO of Pfizer. So, Albert, happy New Year. Thanks for joining us. I know you want to make some quick opening remarks and th ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has approved TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide), for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated. With this approval, TALZENNA is now the first and only PARP inhibitor licensed in the European Union for use with XTANDI for pati ...

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.Shares of this drugmaker have returned +2.4% over the past month versus the Zacks S&P 500 composite's +2.9% change. The Zacks Large Cap Pharmaceuticals industry, to which Pfizer belongs, has gained 6.6% over this period. Now the key question is: Where could the stock be headed in the near term?Although media reports or ...

Pfizer Inc. shares PFE, were downgraded to market perform from outperform at TD Cowen on Thursday, as analysts see upcoming patent expirations and shaky confidence in the drugmaker’s management clouding the outlook. Despite a brutal 2023, when the stock dropped more than 40%, it’s “tough to pound the table even from these levels,” the analysts wrote, adding that expected strong earnings growth through 2026 will be weighed down longer term by losses of market exclusivity on key drugs like the blood thinner ...

Pfizer (PFE) closed at $29.73 in the latest trading session, marking no change from the prior day. This move was narrower than the S&P 500's daily loss of 0.8%. Elsewhere, the Dow saw a downswing of 0.76%, while the tech-heavy Nasdaq depreciated by 1.18%.Prior to today's trading, shares of the drugmaker had gained 2.2% over the past month. This has lagged the Medical sector's gain of 5.8% and the S&P 500's gain of 3.4% in that time.The upcoming earnings release of Pfizer will be of great interest to investo ...

Pfizer Inc (NYSE:PFE) stock moved steadily lower in 2023, closing 11 out of 12 months lower, with March as the only gainer. Though the shares have been on the rise since their Dec. 13 10-year low of $25.76 -- a result of the company's disappointing 2024 forecast -- PFE might not be in the clear just yet. Per data from Schaeffer's Senior Quantitative Analyst Rocky White, Pfizer stock is at the top of the list of the worst stocks to own in January. In the past 10 years, the equity has finished lower eight tim ...